Concord Medical Financials
Concord Medical (CCM) reported $65.9M in revenue for fiscal year 2025, up 25.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025's rebound came from repairing gross economics and overhead, but a creditor-funded balance sheet still shapes the business.
The biggest change was not scale but economics: revenue recovered only modestly, yet gross margin swung from-20.6% to5.6% and selling costs fell enough that the operating loss nearly halved. That means FY2025 looked less like a demand-led comeback and more like the business finally stopped losing money on each unit before interest.
Cash burn now reflects operations more than expansion: operating cash flow was
The balance sheet remains the hard constraint: liabilities still exceeded assets by about
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Concord Medical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Concord Medical, and counted as zero in the overall score.
Not available for Concord Medical, and counted as zero in the overall score.
Concord Medical scores -1.19, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($21.6M) relative to total liabilities ($1.2B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Concord Medical passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Concord Medical reported a net loss of $13.3M while operations used $28.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Concord Medical reported an operating loss of $37.4M against $21.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Concord Medical generated $65.9M in revenue in fiscal year 2025. This represents an increase of 25.2% from the prior year.
Concord Medical's EBITDA was -$16.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 70.8% from the prior year.
Concord Medical reported -$13.3M in net income in fiscal year 2025. This represents an increase of 68.6% from the prior year.
Concord Medical earned -$0.10 per diluted share (EPS) in fiscal year 2025. This represents an increase of 68.8% from the prior year.
Cash & Balance Sheet
Concord Medical recorded an outflow of $36.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 50.9% from the prior year.
Concord Medical held $42.6M in cash against $352.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Concord Medical's gross margin was 5.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 26.2 percentage points from the prior year.
Concord Medical's operating margin was -56.8% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Concord Medical's net profit margin was -20.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 60.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Concord Medical invested $8.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 61.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CCM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.9M+25.2% | $52.6M-30.5% | $75.7M+10.6% | $68.4M-10.2% | $76.2M+123.0% | $34.2M+20.0% | $28.5M+2.6% | $27.8M-45.4% | $50.9M-22.4% | $65.5M-31.1% | $95.2M-2.7% | $97.8M-39.6% | $162.0M+52.4% | $106.3M+48.7% | $71.5M |
| Cost of Revenue | $62.2M-2.0% | $63.4M-26.6% | $86.5M-4.5% | $90.5M+6.4% | $85.1M+164.6% | $32.2M+4.6% | $30.8M+23.6% | $24.9M-30.5% | $35.8M-13.2% | $41.3M-24.3% | $54.5M+23.3% | $44.3M-54.4% | $97.0M+79.1% | $54.1M+113.7% | $25.3M |
| Gross Profit | $3.7M+134.0% | -$10.8M-0.5% | -$10.8M+51.2% | -$22.1M-147.5% | -$8.9M-545.3% | $2.0M+188.2% | -$2.3M-179.1% | $2.9M-80.9% | $15.1M-37.9% | $24.3M-40.3% | $40.6M-24.2% | $53.6M-17.6% | $65.0M+24.6% | $52.2M+13.0% | $46.2M |
| SG&A Expenses | $30.5M-45.0% | $55.4M+19.2% | $46.5M+3.1% | $45.1M-17.3% | $54.6M+20.8% | $45.2M-0.2% | $45.3M+6.6% | $42.4M+16.2% | $36.5M+23.2% | $29.7M+44.5% | $20.5M+137.7% | $8.6M-50.3% | $17.4M+50.8% | $11.5M-10.1% | $12.8M |
| Operating Income | -$37.4M+48.7% | -$72.9M-11.8% | -$65.2M+14.3% | -$76.1M-5.8% | -$71.9M-48.5% | -$48.4M+22.9% | -$62.8M-44.3% | -$43.5M-33.7% | -$32.6M-34.1% | -$24.3M-2638.1% | -$887K-103.0% | $29.6M-0.9% | $29.9M-10.0% | $33.2M+229.4% | -$25.6M |
| Interest Expense | $21.8M-17.7% | $26.5M+13.4% | $23.3M+33.7% | $17.4M+50.7% | $11.6M-7.1% | $12.5M+202.5% | $4.1M-38.7% | $6.7M-51.4% | $13.8M+7.5% | $12.9M+56.6% | $8.2M-4.7% | $8.6M+10.9% | $7.8M+197.7% | $2.6M+154.5% | $1.0M |
| Income Tax | $867K+136.2% | -$2.4M+30.7% | -$3.5M+66.3% | -$10.3M-898.1% | -$1.0M+82.1% | -$5.8M-3.0% | -$5.6M-213.1% | $5.0M+1.4% | $4.9M-43.9% | $8.7M-23.8% | $11.4M-12.3% | $13.0M+4.0% | $12.5M+25.6% | $10.0M+35.6% | $7.4M |
| Net Income | -$13.3M+68.6% | -$42.2M-0.7% | -$41.9M+40.9% | -$71.0M-66.7% | -$42.6M+10.3% | -$47.5M-7.7% | -$44.1M-29.1% | -$34.2M+21.8% | -$43.7M-15.9% | -$37.7M-212.0% | -$12.1M-160.1% | $20.1M+41.6% | $14.2M-32.4% | $21.0M+161.5% | -$34.2M |
| EPS (Diluted) | -$0.10+68.8% | -$0.320.0% | -$0.32+40.7% | -$0.54 | N/A | N/A | N/A | N/A | N/A | -$0.29-222.2% | -$0.09-160.0% | $0.15 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses.
CCM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $936.3M+1.6% | $921.5M+8.1% | $852.7M-2.1% | $870.6M-10.9% | $977.6M+19.6% | $817.6M+32.4% | $617.3M-7.4% | $666.9M+25.2% | $532.6M+14.5% | $465.0M-16.4% | $556.0M+16.6% | $477.0M-29.5% | $676.2M+14.9% | $588.3M+54.7% | $380.3M |
| Current Assets | $134.7M-0.1% | $134.8M+55.1% | $86.9M-21.1% | $110.2M+20.1% | $91.7M-11.5% | $103.6M+155.3% | $40.6M-77.3% | $178.7M+4.6% | $170.8M-0.8% | $172.1M-25.9% | $232.3M-1.5% | $235.9M+9.9% | $214.7M+56.8% | $136.9M+17.5% | $116.6M |
| Cash & Equivalents | $42.6M+43.7% | $29.6M+261.7% | $8.2M-64.3% | $22.9M-7.1% | $24.7M-51.8% | $51.2M+379.9% | $10.7M-81.9% | $58.9M-38.9% | $96.3M+230.0% | $29.2M-58.3% | $69.9M-5.4% | $73.9M+62.0% | $45.6M+266.3% | $12.5M-64.6% | $35.2M |
| Inventory | $6.6M+43.5% | $4.6M-19.4% | $5.7M-53.8% | $12.3M+105.8% | $6.0M+80.4% | $3.3M+430.8% | $624K+27.9% | $488K-49.5% | $966K+13.2% | $853K+41.7% | $602K+25.2% | $481K-85.2% | $3.3M+133.6% | $1.4M | N/A |
| Accounts Receivable | $6.3M-10.1% | $7.0M-32.3% | $10.4M-45.2% | $18.9M-5.9% | $20.1M+69.3% | $11.9M+12.0% | $10.6M-16.2% | $12.6M-37.7% | $20.3M-25.7% | $27.3M-19.0% | $33.7M-21.1% | $42.7M-17.6% | $51.9M+53.6% | $33.8M-13.0% | $38.8M |
| Goodwill | $81.8M0.0% | $81.8M+3.8% | $78.8M-2.7% | $81.0M-3.9% | $84.4M+151.6% | $33.5M+4.0% | $32.3M+35.9% | $23.7M | $0 | N/A | N/A | N/A | $47.2M-2.4% | $48.4M | N/A |
| Total Liabilities | $1.2B+0.2% | $1.2B+7.2% | $1.2B+0.9% | $1.1B-4.3% | $1.2B+29.8% | $919.2M+44.8% | $634.9M+5.2% | $603.3M+60.2% | $376.6M+31.0% | $287.6M-14.1% | $334.6M+79.1% | $186.8M-31.9% | $274.2M+28.9% | $212.7M+276.8% | $56.5M |
| Current Liabilities | $279.5M-4.0% | $291.2M+5.9% | $274.8M+69.1% | $162.6M+28.8% | $126.2M+60.8% | $78.5M-12.9% | $90.1M-28.8% | $126.6M-25.7% | $170.3M+24.3% | $137.0M-41.3% | $233.3M+88.0% | $124.1M-36.1% | $194.0M+40.6% | $138.0M+300.8% | $34.4M |
| Long-Term Debt | $352.6M-4.5% | $369.0M+31.4% | $280.9M-21.6% | $358.3M+4.8% | $341.9M+13.3% | $301.6M+62.6% | $185.6M+156.4% | $72.4M+65.4% | $43.7M+40.8% | $31.1M-26.3% | $42.2M-22.0% | $54.1M+0.7% | $53.7M+11.1% | $48.3M+179.6% | $17.3M |
| Total Equity | -$300.7M+3.7% | -$312.4M-4.5% | -$298.9M-10.6% | -$270.3M-25.7% | -$215.0M-111.6% | -$101.6M-476.2% | -$17.6M-127.7% | $63.6M-55.7% | $143.6M-14.5% | $168.0M-21.8% | $214.8M-25.9% | $289.7M-17.3% | $350.5M+7.5% | $326.1M+6.1% | $307.4M |
| Retained Earnings | -$638.6M-6.6% | -$599.1M-4.6% | -$572.5M-4.8% | -$546.2M-6.2% | -$514.3M-36.6% | -$376.5M-46.8% | -$256.5M-43.0% | -$179.3M-32.7% | -$135.2M-56.9% | -$86.2M-65.9% | -$51.9M-24.9% | -$41.6M+34.3% | -$63.3M+15.9% | -$75.3M+21.0% | -$95.3M |
CCM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.9M+47.0% | -$54.5M-39.9% | -$38.9M-24.0% | -$31.4M+44.3% | -$56.4M-60.1% | -$35.2M-25.5% | -$28.1M-399.8% | -$5.6M-236.7% | $4.1M+136.5% | -$11.2M+58.4% | -$27.0M-134.2% | $79.0M+84.7% | $42.8M+2.7% | $41.7M+91.2% | $21.8M |
| Capital Expenditures | $8.1M-61.0% | $20.7M+29.8% | $15.9M-50.8% | $32.3M-26.2% | $43.8M+70.0% | $25.8M-23.0% | $33.4M+38.8% | $24.1M+71.7% | $14.0M+23.4% | $11.4M+54.1% | $7.4M-11.1% | $8.3M-32.6% | $12.3M+16.4% | $10.6M+263.4% | $2.9M |
| Free Cash Flow | -$36.9M+50.9% | -$75.1M-37.0% | -$54.9M+13.9% | -$63.7M+36.4% | -$100.2M-64.3% | -$61.0M+0.8% | -$61.5M-107.0% | -$29.7M-199.4% | -$9.9M+56.1% | -$22.6M+34.3% | -$34.4M-148.6% | $70.7M+132.1% | $30.5M-1.9% | $31.1M+64.7% | $18.9M |
| Investing Cash Flow | $7.7M+109.5% | -$81.3M-1110.7% | -$6.7M+61.0% | -$17.2M+80.6% | -$88.8M-8.5% | -$81.8M+46.8% | -$153.9M-5.8% | -$145.5M-202.4% | -$48.1M | N/A | -$60.4M-230.5% | $46.3M+309.7% | -$22.1M+79.2% | -$105.8M-34.6% | -$78.6M |
| Financing Cash Flow | $28.2M-82.0% | $157.0M+332.6% | $36.3M-34.7% | $55.5M-44.9% | $100.8M-42.2% | $174.5M+136.6% | $73.7M-57.9% | $175.0M+485.6% | $29.9M | N/A | $91.1M+197.6% | -$93.3M-827.0% | $12.8M-68.7% | $41.1M+518.7% | $6.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $41.2M | N/A | $73.1M | N/A | N/A | $8.8M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $4.4M+43.8% | $3.0M | N/A | $994K-85.8% | $7.0M+535.4% | $1.1M |
CCM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.6%+26.2pp | -20.6%-6.4pp | -14.3%+18.0pp | -32.3%-20.6pp | -11.7%-17.6pp | 5.9%+13.9pp | -8.0%-18.3pp | 10.3%-19.3pp | 29.6%-7.4pp | 37.0%-5.7pp | 42.7%-12.1pp | 54.8%+14.6pp | 40.2%-8.9pp | 49.1%-15.5pp | 64.6% |
| Operating Margin | -56.8% | -138.6% | -86.2% | -111.2% | -94.4% | -141.7% | -220.4% | -156.8% | -64.0%-27.0pp | -37.1%-36.1pp | -0.9%-31.2pp | 30.3%+11.8pp | 18.4%-12.8pp | 31.2%+67.0pp | -35.8% |
| Net Margin | -20.2%+60.1pp | -80.3%-24.9pp | -55.4% | -103.7% | -55.9% | -139.0% | -154.8% | -123.0% | -85.9%-28.3pp | -57.6%-44.9pp | -12.7%-33.3pp | 20.5%+11.8pp | 8.8%-11.0pp | 19.8%+67.5pp | -47.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -53.7%-23.3pp | -30.4%-8.0pp | -22.5%-16.8pp | -5.6%-12.6pp | 6.9%+2.9pp | 4.0%-2.4pp | 6.4%+17.5pp | -11.1% |
| Return on Assets | -1.4%+3.2pp | -4.6%+0.3pp | -4.9%+3.2pp | -8.2%-3.8pp | -4.4%+1.4pp | -5.8%+1.3pp | -7.1%-2.0pp | -5.1%+3.1pp | -8.2%-0.1pp | -8.1%-5.9pp | -2.2%-6.4pp | 4.2%+2.1pp | 2.1%-1.5pp | 3.6%+12.6pp | -9.0% |
| Current Ratio | 0.480.0x | 0.46+0.1x | 0.32-0.4x | 0.680.0x | 0.73-0.6x | 1.32+0.9x | 0.45-1.0x | 1.41+0.4x | 1.00-0.3x | 1.26+0.3x | 1.00-0.9x | 1.90+0.8x | 1.11+0.1x | 0.99-2.4x | 3.39 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.14+0.8x | 0.30+0.1x | 0.180.0x | 0.200.0x | 0.190.0x | 0.150.0x | 0.15+0.1x | 0.06 |
| FCF Margin | -56.1% | -142.9% | -72.5%+20.7pp | -93.1% | -131.4% | -178.4% | -215.8% | -107.0% | -19.5%+15.0pp | -34.5%+1.7pp | -36.2%-108.5pp | 72.3%+53.5pp | 18.8%-10.4pp | 29.2%+2.8pp | 26.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$300.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.48), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Concord Medical Ranks
Frequently Asked Questions
What is Concord Medical's annual revenue?
Concord Medical (CCM) reported $65.9M in total revenue for fiscal year 2025. This represents a 25.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Concord Medical's revenue growing?
Concord Medical (CCM) revenue grew by 25.2% year-over-year, from $52.6M to $65.9M in fiscal year 2025.
Is Concord Medical profitable?
No, Concord Medical (CCM) reported a net income of -$13.3M in fiscal year 2025, with a net profit margin of -20.2%.
What is Concord Medical's EBITDA?
Concord Medical (CCM) had EBITDA of -$16.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Concord Medical have?
As of fiscal year 2025, Concord Medical (CCM) had $42.6M in cash and equivalents against $352.6M in long-term debt.
What is Concord Medical's gross margin?
Concord Medical (CCM) had a gross margin of 5.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Concord Medical's operating margin?
Concord Medical (CCM) had an operating margin of -56.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Concord Medical's net profit margin?
Concord Medical (CCM) had a net profit margin of -20.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Concord Medical's free cash flow?
Concord Medical (CCM) recorded an outflow of $36.9M in free cash flow during fiscal year 2025. This represents a 50.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Concord Medical's operating cash flow?
Concord Medical (CCM) recorded an outflow of $28.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Concord Medical's total assets?
Concord Medical (CCM) had $936.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Concord Medical's capital expenditures?
Concord Medical (CCM) invested $8.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Concord Medical's current ratio?
Concord Medical (CCM) had a current ratio of 0.48 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Concord Medical's return on assets (ROA)?
Concord Medical (CCM) had a return on assets of -1.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Concord Medical's cash runway?
Based on fiscal year 2025 data, Concord Medical (CCM) had $42.6M in cash against an annual operating cash burn of $28.9M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Concord Medical's debt-to-equity ratio negative or not reported?
Concord Medical (CCM) has negative shareholder equity of -$300.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Concord Medical's Altman Z-Score?
Concord Medical (CCM) has an Altman Z-Score of -1.19, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Concord Medical's Piotroski F-Score?
Concord Medical (CCM) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Concord Medical's earnings high quality?
Concord Medical (CCM) reported a net loss of $13.3M while operations used $28.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Concord Medical cover its interest payments?
Concord Medical (CCM) reported an operating loss of $37.4M against $21.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Concord Medical?
Concord Medical (CCM) scores 26 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.